Mylan Wins Summary Judgment against Sanofi in EpiPen Litigation
"Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi Inc's baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company's commitment to vigorously defend itself against unfounded claims," the company said in its recent statement
Pittsburgh: Viatris Inc. has recently announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen products. Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi's baseless attempts to argue that Mylan used anticompetitive practices...
Pittsburgh: Viatris Inc. has recently announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen products.
Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi's baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company's commitment to vigorously defend itself against unfounded claims.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd